GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Mar 31, 2026

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-26-000050General Corporate
Debt relative to revenue20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

128.57% · OPTIONAL · VALID

Capex intensity60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.56% · OPTIONAL · VALID

Operating cash generation90thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

24.58% · OPTIONAL · VALID

Revenue growth35thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

20.46% · CORE · VALID

Inventory pressure25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

60.42% · OPTIONAL · VALID

Operating margin100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

16.38% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

4.46% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.29% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
34.99%
Current
128.57%
Delta
93.57%
Capex Intensity Increased
Previous
1.57%
Current
2.56%
Delta
0.99%
Cash Generation Increased
Previous
20.97%
Current
24.58%
Delta
3.61%
Growth Decreased
Previous
43.78%
Current
20.46%
Delta
-23.32%
Inventory Pressure Increased
Previous
16.20%
Current
60.42%
Delta
44.22%
Profitability Increased
Previous
12.58%
Current
16.38%
Delta
3.80%
R And D Intensity Decreased
Previous
5.85%
Current
4.46%
Delta
-1.38%
Sbc Intensity Decreased
Previous
4.29%
Current
4.29%
Delta
-0.00%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.